Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells.
Argonaute (Ago) 2 is the catalytic engine of mammalian RNA interference, but little is known concerning the regulation of Ago2 by cell-signaling pathways. In this study we show that expression of Ago2, but not Ago1, Ago3, or Ago4, is elevated in estrogen receptor (ER) alpha-negative (ERalpha(-)) vs. ERalpha-positive (ERalpha+) breast cancer cell lines, and in ERalpha(-) breast tumors. In MCF-7 cells the low level of Ago2 was found to be dependent upon active ERalpha/estrogen signaling. Interestingly, the high expression of Ago2 in ERalpha(-) cells was severely blunted by inhibition of the epidermal growth factor (EGF) receptor/MAPK signaling pathway, using either a pharmacological MAPK kinase inhibitor, U0126, or a small interfering RNA directed against EGF receptor. Half-life studies using cycloheximide indicated that EGF enhanced, whereas U0126 decreased, Ago2 protein stability. Furthermore, a proteosome inhibitor, MG132, blocked Ago2 protein turnover. The functional consequences of elevated Ago2 levels were examined by stable transfection of ERalpha+ MCF-7 cells with full-length and truncated forms of Ago2. The full-length Ago2 transfectants displayed enhanced proliferation, reduced cell-cell adhesion, and increased migratory ability, as shown by proliferation, homotypic aggregation, and wound healing assays, respectively. Overexpression of full-length Ago2, but not truncated forms of Ago2 or an empty vector control, reduced the levels of E-cadherin, beta-catenin, and beta-actin, as well as enhanced endogenous miR-206 activity. These data indicate that Ago2 is regulated at both the transcriptional and posttranslational level, and also implicate Ago2 and enhanced micro-RNA activity in the tumorigenic progression of breast cancer cell lines.
Adams
Brian D
BD
Department of Cell Biology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, Connecticut 06030-3505, USA.
Claffey
Kevin P
KP
White
Bruce A
BA
D060565:Argonaute Proteins; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D002449:Cell Aggregation; D002465:Cell Movement; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D003513:Cycloheximide / Q000494:pharmacology; D018450:Disease Progression; D066246:ErbB Receptors / Q000502:physiology*; D015852:Eukaryotic Initiation Factor-2 / Q000235:genetics*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics; D010641:Phenotype; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics*; D034741:RNA, Small Interfering / Q000235:genetics; D014945:Wound Healing
C466422:AGO2 protein, human; D060565:Argonaute Proteins; D015852:Eukaryotic Initiation Factor-2; D035683:MicroRNAs; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D003513:Cycloheximide; D066246:ErbB Receptors; D048049:Extracellular Signal-Regulated MAP Kinases
Trends Cell Biol. 2007 Mar;17(3):118-26
17197185
J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):85-94
10819507
Science. 2004 Sep 3;305(5689):1434-7
15284453
Cancer Res. 1984 Aug;44(8):3442-7
6331647
Nat Rev Cancer. 2006 Apr;6(4):259-69
16557279
Mol Cell. 2007 Jun 8;26(5):611-23
17560368
J Biol Chem. 2008 Jan 11;283(2):1026-33
17991735
Curr Biol. 2004 Sep 7;14(17):R719-21
15341765
Biochem Biophys Res Commun. 2007 Apr 13;355(3):707-14
17307140
Mol Cell. 2004 Jul 23;15(2):185-97
15260970
Curr Opin Struct Biol. 2005 Jun;15(3):331-41
15925505
Cancer Res. 2001 Sep 1;61(17):6583-91
11522658
Trends Biochem Sci. 2006 Nov;31(11):622-30
17029813
Oncologist. 2006 Jan;11(1):1-8
16401708
Genes Dev. 2006 Oct 15;20(20):2769-72
17043305
Nature. 2002 Jan 31;415(6871):530-6
11823860
Oncogene. 2007 May 14;26(22):3113-21
17496910
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Science. 2001 Aug 10;293(5532):1146-50
11498593
Steroids. 2007 Feb;72(2):188-201
17173941
Cell Res. 2008 Mar;18(3):350-9
18270520
Genes Dev. 2005 Jul 15;19(14):1680-5
16024657
Genomics. 2007 Jun;89(6):687-96
17418524
Genes Dev. 2002 Nov 1;16(21):2733-42
12414724
Mol Endocrinol. 2004 Jun;18(6):1411-27
15001666
Oncogene. 2004 Mar 15;23(11):2079-88
15021895
Cell. 2002 Sep 6;110(5):563-74
12230974
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2438-43
12604776
RNA. 2005 Jun;11(6):849-52
15872185
Cell. 2007 Jun 15;129(6):1141-51
17524464
RNA. 2008 Jun;14(6):1244-53
18430891
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
7612182
Mol Cell Biol. 2006 Mar;26(5):1898-907
16479008
Nucleic Acids Res. 2006 Feb 14;34(4):1092-101
16478716
Science. 1984 Oct 26;226(4673):409-16
6494891
Pharmacol Ther. 1999 May-Jun;82(2-3):241-50
10454201
Mol Cancer Res. 2006 Oct;4(10):695-707
17050664
Biochem J. 2008 Aug 1;413(3):429-36
18476811
Cell. 2000 Jan 7;100(1):57-70
10647931
Cell. 2004 Jun 25;117(7):927-39
15210113
Cancer Res. 2006 Apr 1;66(7):3903-11
16585219
Mol Cell Biol. 2006 Apr;26(8):2965-75
16581772
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
16514137
Nat Cell Biol. 2006 Dec;8(12):1359-68
17115032
Genes Dev. 2007 Aug 15;21(16):1999-2004
17626790
Science. 2004 Sep 3;305(5689):1437-41
15284456
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4034-9
16495412
Genome Biol. 2007;8(10):R214
17922911
Mol Endocrinol. 2007 May;21(5):1132-47
17312270
PLoS Genet. 2007 Dec 28;3(12):e227
18166081
Nature. 2004 Nov 11;432(7014):235-40
15531877
Lung Cancer. 2006 Oct;54(1):25-33
16872715
Cell. 2005 Aug 26;122(4):553-63
16122423
Cancer Res. 2007 Nov 15;67(22):11001-11
18006846
Mol Cell. 2005 Aug 5;19(3):405-19
16061186
Nat Struct Mol Biol. 2005 Feb;12(2):133-7
15643423
Nature. 2004 Sep 16;431(7006):343-9
15372041
Science. 2005 Sep 2;309(5740):1573-6
16081698
BMC Genomics. 2006 Apr 27;7:96
16643655